Reports Q3 revenue $1.28B, consensus $1.28B. “We’re delivering on the vision we laid out in 2023, with a base business engine that continues to hum and steady introduction of innovative products across categories,” said Brent Saunders, chairman and CEO, Bausch + Lomb (BLCO). “Our loaded and differentiated pipeline featuring clinical-stage programs will be on full display in just a few weeks at investor day.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Activist Jana Partners Takes Stake in Cooper Companies, Presses for Strategic Review
- Jana built Cooper Companies stake, will push for deal, WSJ reports
- Bausch + Lomb price target raised to C$16 from C$15 at Citi
- Bausch + Lomb initiated with a Neutral at Goldman Sachs
- Bausch + Lomb to Announce Q3 2025 Results and Host Investor Day